Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan’s 1st Biosimilars for Eylea, Actemra Get NHI Listing in November
The first biosimilar version of Eylea (aflibercept) in Japan will be granted NHI reimbursement on November 12, with Fuji Pharma being the only company moving ahead with listing, according to the government’s official gazette issued on November 11. Japan has…
To read the full story
Related Article
- Celltrion Sets April 28 Launch Date for Japan’s 1st Actemra Biosimilar
February 17, 2026
- Celltrion to Launch Japan’s First Actemra Biosimilar in Late April
February 12, 2026
- Fuji Says Eylea Biosimilar Patent Risk Cleared under Global Settlement
February 2, 2026
- Top Court Rejects Samsung Challenge to Patent-Linkage Disclosures in Eylea Biosimilar Case
January 27, 2026
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
- Santen to Market Bayer’s Eylea Bio-AG; Launch Date Still Undisclosed
December 8, 2025
- Eylea Bio-AG to Carry DME Indication Missing from Fuji’s Biosimilar Label
December 5, 2025
- Bayer’s Eylea Bio-AG Finally Reaches NHI Listing amid Reform Talks
December 4, 2025
- Bayer, Regeneron Move to Block Fuji’s Newly Listed Eylea Biosimilar in Japan
November 13, 2025
- Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
October 7, 2025
- Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME
October 6, 2025
- Japan OKs Biosimilars of Eylea, Actemra, Simponi, Ranmark in Likely First Debut
September 22, 2025
REGULATORY
- MHLW Orders Colchicine Label Revision, Warns against Doses above 1.5 mg per Day
February 26, 2026
- LDP Panel Delays Approval of Health Insurance Bill amid Concerns over OTC-Like Drug Charges
February 26, 2026
- Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
February 26, 2026
- Symbicort Switch to OTC Status Gains No Support at MHLW Panel
February 25, 2026
- Japan Govt Council Finalizes Recommendations for National MCM Strategy
February 25, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…